$23,619.79 speaking Payment -- Boehringer Ingelheim to Dr. Eric Sanchez

Boehringer Ingelheim compensates Pulmonologist Eric Sanchez for Xarelto speaking services

This page provides a detailed analysis of a $23,619.79 speaking payment from Boehringer Ingelheim to Dr. Eric Sanchez. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$23,619.79
Payment Typespeaking
Payment NatureCompensation for serving as faculty or as a speaker
Pharmaceutical CompanyBoehringer Ingelheim
PhysicianDr. Eric Sanchez
NPI Number1865986147
Physician SpecialtyPulmonology
LocationToledo, OH
Date of Payment2024-10-07
Related Drug/DeviceXarelto
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Boehringer Ingelheim made a $23.6K speaking payment to Eric Sanchez, a Pulmonology specialist in Toledo, OH. The payment was associated with Xarelto. Boehringer Ingelheim paid Dr. Eric Sanchez $23,619.79 on October 7, 2024, for speaking engagements related to Xarelto. This payment represents compensation for Dr. Sanchez's role as faculty or speaker. The payment was made to Dr. Sanchez, a Pulmonology specialist located in Toledo, OH.

Patient Guidance: What This Payment Means for You

If your doctor receives payments for speaking about medications, it's important to understand if this influences their prescribing habits and to discuss all treatment options openly. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for speaking engagements are common in the pharmaceutical industry, particularly for specialists who educate peers on new or complex therapies like Xarelto.

Regulatory Context: Sunshine Act Requirements

Payments to physicians for speaking engagements are subject to disclosure under the Sunshine Act (part of the Affordable Care Act) to promote transparency in the healthcare industry.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $23.6K payment for?

This was a speaking payment of $23.6K from Boehringer Ingelheim to Eric Sanchez, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Xarelto. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Eric Sanchez accept pharmaceutical money?

Yes, Eric Sanchez received this $23.6K payment from Boehringer Ingelheim. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Eric Sanchez's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $23.6K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Pulmonology?

To compare this payment against Pulmonology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Pulmonology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Eric Sanchez's relationship with Boehringer Ingelheim?

The payment amount is substantial, suggesting significant speaking activity. This $23.6K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Pulmonology?

The payment is specifically for 'Compensation for serving as faculty or as a speaker'.

What should patients do after learning about this payment?

If your doctor receives payments for speaking about medications, it's important to understand if this influences their prescribing habits and to discuss all treatment options openly.

What else should I know about this speaking payment?

Xarelto is a anticoagulant medication, commonly prescribed for conditions like deep vein thrombosis and atrial fibrillation.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.